Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trial

INTRODUCTION: Human amniotic fluid (hAF) has been shown to reduce inflammation in multiple experimental models. hAF has previously been approved by the US Food and Drug Administration (FDA) as a human cellular and tissue product for tissue injury for human administration, and used safely in thousand...

Descripción completa

Detalles Bibliográficos
Autores principales: Tonna, Joseph E, Pierce, Jan, Hatton, Nathan, Lewis, Giavonni, Phillips, John D, Messina, Alyssa, Skidmore, Chloe R, Taylor, Kirsten, Selzman, Craig H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Intensive Care
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880092/
https://www.ncbi.nlm.nih.gov/pubmed/33574155
http://dx.doi.org/10.1136/bmjopen-2020-045162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7880092/
https://www.ncbi.nlm.nih.gov/pubmed/33574155
http://dx.doi.org/10.1136/bmjopen-2020-045162

Ejemplares similares